Clipping of news on Brazilian Culture, Law and Citizenship
06/09/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
transparent image
A preventive vaccine against HIV , the first in the world with the killed virus genetically modified ( SAV001 - H ) , was successfully tested .
The vaccine was developed by scientist Chil - Yong Kang and his team at Western University in Ontario (Canada ) , in partnership with the pharmaceutical company Sumagen Canada.
A phase I clinical study ( SAV CT 01 ) was completed without adverse effects in all patients . Human trials took place from March 2012 to August 2013. The survey gathered HIV-infected patients asymptomatic , between 18 and 50 years old . The members of the study were divided into two groups randomly . One group was treated with the new vaccine and the other with placebo.
Adverse events after vaccination were recorded daily by volunteers , who visited the test sites at weeks 4 , 6 , 12 , 18 , 26 and 52 after vaccination , undergoing hematological , clinical , urinalysis and physical .
In addition to the security assessment tests for HIV-specific antibodies were performed over the entire monitoring period .
According to the study , antibodies to p24 antigen increased 64 times and against the antigen gp120 up to eight times post vaccination . According to researchers, the increase in antibody levels were maintained during the study period of 52 weeks.
" The rates of increase in antibody production resulting vaccine are encouraging , since predict success in human clinical trial phase 2 which will measure immune responses , " said Chil -Yong Kang .
During disclosure, representatives Sumagem said they were confident in the development of SAV001 - H as the first HIV vaccine preventive able to save millions of lives .
According to Jung - Gee Cho , CEO Sumagen , " after proof of vaccine safety , following the standards of the Food and Drug Administration ( FDA ) , the team is prepared to take the next steps toward Phase II, clinical trials Phase III .
" We are opening the doors to participation of pharmaceutical companies , governments and charitable organization , seeking new partnerships that can bring us closer to creating the first commercial vaccine against HIV .
Source : Website pheeno
Our news are taken in full from our partner sites . For this reason , we can not change the contents of the same even in cases of typos .
transparent image
This article was translated by an automatic translation system, and was therefore not reviewed by people.